HWAM
AVDL

Hennion & Walsh Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Hennion & Walsh Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-112,275
Closed -$2.42M – 934
2025
Q4 		$2.42M Buy
112,275
+26,731
+31% +$519K 0.08% 309
2025
Q3 		$1.31M Buy
85,544
+35,208
+70% +$458K 0.05% 449
2025
Q2 		$445K Buy
+50,336
New +$442K 0.02% 708

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Hennion & Walsh Asset Management's AVDL Position: Q1 2026 in Review

Hennion & Walsh Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 112,275 shares — an estimated $2.42M sold.

Hennion & Walsh Asset Management first reported a position in AVDL in Q2 2025 and held it in 3 quarters. The position peaked at $2.42M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Hennion & Walsh Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 112,275 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2.42M.
  • Hennion & Walsh Asset Management first reported a position in Avadel Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Hennion & Walsh Asset Management's Avadel Pharmaceuticals position peaked at $2.42M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q1 2026, filed 13 May 2026.